Search Results
Your search for The A matches 32752 pages
Showing 2451 - 2500Novel Vaccine May Delay Relapse in KRAS-Mutated Pancreatic and Colorectal Cancers
A novel vaccine may be effective at preventing relapse in patients with KRAS-mutated pancreatic and colorectal cancers, according to a recent study published by Pant et al in Nature Medicine. Background KRAS-mutated cancers make up about 25% of all solid tumors, including 90% of pancreatic cancer...
Attitudes Toward Climate Change May Impact Cancer Screening Behavior
Investigators have discovered that individuals who view climate change as a health threat may be more likely to undergo cancer screening, according to a recent study published by Qian et al in the Journal of the National Cancer Institute. The recent findings supported the development of public...
Atezolizumab Plus Carboplatin in Metastatic Triple-Negative Breast Cancer
Researchers have evaluated the efficacy of atezolizumab in combination with carboplatin in patients with triple-negative breast cancer, according to a recent study published by Lehmann et al in JAMA Oncology. The new findings may help researchers better understand biomarkers of immunotherapy...
Real-World Data Show Impact of Immunotherapy in Populations Underrepresented in Lung Cancer Clinical Trials
New research published by Lee et al in JNCCN—Journal of the National Comprehensive Cancer Network found patients treated with first-line immunotherapy for advanced non–small cell lung cancer (NSCLC) had similar results in terms of overall survival, progression-free survival, and treatment duration, ...
Expert Point of View: Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, commented on the findings of the PREFERABLE-EFFECT trial: “This is a wonderful study about what has been obvious to all of us—exercise improves quality of life. Most oncologists probably recommend it, but not necessarily in the structured and rigorous way this study did. We...
Patients With Advanced Breast Cancer May Gain Multiple Benefits From Exercise as Part of Palliative Care
Although current ASCO guidelines recommend exercise for patients with breast cancer during adjuvant therapy with curative intent, the guidelines state that more study is needed regarding the effects of exercise for patients with metastatic breast cancer. The results of the PREFERABLE-EFFECT trial...
Some Patients With Breast Cancer May Safely Avoid Locoregional Irradiation After Neoadjuvant Chemotherapy
It may be possible for some patients with breast cancer to avoid adjuvant regional nodal irradiation safely, according to the results of the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the 2023 San Antonio Breast Cancer Symposium.1 These findings particularly apply to patients...
Triple-Negative Breast Cancer: Several Treatment Response Trajectories Identified
Investigators analyzed cells within triple-negative breast cancers before and after radiation therapy combined with pembrolizumab and identified three patient groups with different responses to the treatment. Their study, published by Shiao et al in Cancer Cell, found that for some patients with...
New Study Uncovers Factors Potentially Contributing to Development of Colitis in Patients Undergoing Cancer Immunotherapy
Researchers may have uncovered a mechanism contributing to the development of colitis in patients with cancer receiving immunotherapy as well as a novel strategy to deliver immune-based therapy without causing the adverse side effect, according to a recent study published by Lo et al in Science....
Patient Choice of Location for Breast Cancer Surgery
Investigators have found that involving patients as partners in the treatment decision-making process may be a critical aspect of patient-centered care, according to a recent study published by Aggarwal et al in Cancer. Study Methods and Results In the study, the investigators used 2016 to 2018...
Leisure-Time Physical Activity and Breast Cancer Risk in Premenopausal Women
As reported in the Journal of Clinical Oncology by Timmins et al, a pooled analysis of 19 international cohorts showed that high vs low self-reported leisure-time physical activity was associated with a reduced risk of premenopausal breast cancer. Study Details The study used individual-level data ...
Non–Locally Advanced Rectal Cancer: Impact of Reduced Use of Neoadjuvant Radiotherapy
In a Dutch nationwide cross-sectional cohort study reported in JAMA Oncology, Hazen et al found that a reduced use of neoadjuvant radiotherapy as part of chemoradiotherapy was not associated with poorer outcomes in patients with non–locally advanced rectal cancer. As stated by the investigators,...
Long-Term Results With Front-Line Dasatinib/Blinatumomab for Philadelphia Chromosome–Positive ALL
As reported in the Journal of Clinical Oncology by Foà et al, long-term results of the Italian D-ALBA study have shown that a chemotherapy-free induction/consolidation regimen of dasatinib followed by blinatumomab maintained highly favorable outcomes in the front-line treatment of adult patients...
Lapatinib Increases Overall Survival in Patients With Metastatic Breast Cancer and HER2-Positive CTCs
A recent study showed that the HER2-targeted tyrosine kinase inhibitor lapatinib was associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs). These findings were published by Fehm et al in Clinical...
Comparing Outcomes of Robotic and Laparoscopic Surgeries for Colorectal Cancer
Robotic surgery may offer significant benefits over laparoscopic procedures in patients with colorectal cancer undergoing colectomies, according to a recent study published by Farah et al in the World Journal of Surgical Oncology. These findings suggest that a majority of patients receiving robotic ...
Minimizing the Severe Side Effects of Immunotherapy in Patients With Multiple Myeloma
Investigators have found that providing prophylactic treatment with the biological agent tocilizumab prior to immunotherapy may reduce the incidence of cytokine-release syndrome in patients with multiple myeloma, according to a study published by Kowalski et al in Blood Cancer Discovery. ...
Michael Wang, MD, on Mantle Cell Lymphoma: New Results on Ibrutinib Plus Venetoclax
Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the Sympatico study, which shows the combination of ibrutinib and venetoclax improved progression-free survival vs ibrutinib plus placebo in patients with relapsed or refractory mantle cell...
Muscle-Invasive Bladder Cancer: 5-Year Survival With dd-MVAC
As reported in The Lancet Oncology by Pfister et al, a 5-year analysis of the French phase III VESPER trial showed no improvement in overall survival with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) vs gemcitabine and cisplatin (GC) in the total perioperative...
Addition of SBRT to Standard-of-Care Systemic Therapy in Oligoprogressive Disease
In the phase II CURB trial reported in The Lancet, Chiaojung Jillian Tsai, MD, PhD, and colleagues found that the addition of stereotactic body radiotherapy (SBRT) to standard-of-care systemic therapy was associated with improved progression-free survival in the total study population of patients...
Perioperative Pembrolizumab Plus Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
As reported in The Lancet Oncology by Kohei Shitara, MD, and colleagues, interim analyses of the phase III KEYNOTE-585 trial have shown that the addition of perioperative pembrolizumab to chemotherapy improved pathologic complete response, but did not significantly improve event-free survival, in...
Baseline Estradiol and Prevention of Breast Cancer in High-Risk Postmenopausal Women
In an analysis from the IBIS-II prevention trial reported in The Lancet Oncology, Jack Cuzick, PhD, and colleagues found that increasing the ratio of baseline estradiol level to sex hormone–binding globulin (SHBG) was associated with an increased risk of breast cancer in high-risk postmenopausal...
Treatment at Community Cancer Centers May Be Linked to Poorer Outcomes in Patients With HPV-Related Oropharyngeal Squamous Cell Carcinoma
Treatment in community cancer centers may be associated with a lower rate of survival among patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma of the oropharynx, according to a recent study published by Trakimas et al in the Journal of the National Cancer...
Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer
A rare subset of T cells called V-delta 1 gamma-delta (Vd1-gd) T cells could help predict which patients with advanced skin cancer may be responsive to immunotherapy, according to a novel study published by Davies et al in Nature Cancer. The new findings may lead to the development of new and more...
Jennifer A. Woyach, MD, on CLL/SLL: 30-Month Follow-up and Subgroup Analysis of Pirtobrutinib
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses phase I/II findings of the BRUIN study on the use of pirtobrutinib after covalent Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma...
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
Peter Schmid, MD, PhD, on Early-Stage TNBC: Updated Survival Results From KEYNOTE-522
Peter Schmid, MD, PhD, of Queen Mary University of London and Barts Cancer Institute, discusses phase III findings from KEYNOTE-522 showing that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to show a clinically meaningful improvement in event-free...
Overall Survival With Atezolizumab/Chemotherapy vs Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Carcinoma
In a final overall survival analysis of the phase III IMvigor130 trial reported in The Lancet Oncology, Enrique Grande, MD, and colleagues found no significant advantage in overall survival with atezolizumab plus chemotherapy vs chemotherapy alone in the first-line treatment of patients with...
MRD-Guided Ibrutinib/Venetoclax for Previously Untreated Patients With CLL
As reported in The New England Journal of Medicine by Talha Munir, MBBS, and colleagues, an analysis from the UK phase III FLAIR trial showed improved progression-free survival with measurable residual disease (MRD)-guided ibrutinib/venetoclax vs fludarabine/cyclophosphamide/rituximab (FCR) in...
Next-Generation Sequencing May Help Improve Access to Immunotherapy Among Patients With Cancer and Mismatch Repair Deficiency
Next-generation sequencing may help better identify patients with cancer and mismatch repair deficiency who may benefit from immunotherapy, according to a recent study published by Farhat et al in Cancer Cell. The new findings indicated that treating more patients with immunotherapy may require...
Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel may be a cost-effective second-line treatment option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Choe et al in Blood Advances. Background In cases...
2023 Members Appointed to the National Cancer Advisory Board
In addition to Dr. Richard J. Boxer, the following names have been newly appointed to serve a 5-year term on the National Cancer Institute’s National Cancer Advisory Board: Margaret Anne Anderson, Managing Director of Deloitte Consulting LLP, Arlington, Virginia Ysabel Duron, Founder and Executive ...
How Being a Member of the President’s National Cancer Advisory Board Is Contributing to High-Quality Oncology Care
This past year, President Joe Biden announced the appointment of six members to the National Cancer Advisory Board (NCAB; see related article). This board plays a crucial role in advising and assisting the director of the National Cancer Institute (NCI) in setting the activities of the national...
Expert Point of View: Noemí Reguart, MD, PhD
Abstract discussant Noemí Reguart, MD, PhD, an oncologist at the Hospital Clinic Barcelona, underscored the “impressive” progression-free and overall survival results of the phase III ETER701 trial, which have “never been achieved before in extensive-stage small cell lung cancer.” According to...
Phase III Trial Shows Novel Four-Drug Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...
Potential Clinical Uses of Identifying New Hematologic Malignancy Predisposition Gene
Hamish S. Scott, PhD, and Chris Hahn, PhD, both of Australia’s SA Pathology and Centre for Cancer, discuss ERG, a new predisposition gene for bone marrow failure and hematologic malignancy. Identifying causal germline ERG variants has direct clinical implications for diagnosis, counseling,...
Can Immunotherapy Induce Sustained Disease Control Among Patients With Colorectal Cancer?
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, and the third-leading cause of cancer-related deaths. According to the American Cancer Society, in 2023, it is estimated that about 52,550 individuals died from the...
Addition of Atezolizumab to Bevacizumab and Chemotherapy in Metastatic, Persistent, or Recurrent Cervical Cancer
As reported in The Lancet by Ana Oaknin, MD, and colleagues, the phase III BEATcc trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy improved progression-free and overall survival in women with metastatic, persistent, or recurrent cervical cancer. Study Details The...
Incidence of Second Primary Cancers in Adult Cancer Survivors
In a Danish population-based retrospective cohort study reported in The Lancet Oncology, Kjaer et al identified the cumulative incidence of second primary cancers among cancer survivors aged ≥ 40 years who were alive 1 year after diagnosis. Study Details The study involved data from 457,334...
IMvigor130: Atezolizumab vs Chemotherapy in Locally Advanced or Metastatic Urothelial Carcinoma
In the final overall survival analysis from the phase III IMvigor130 trial reported in The Lancet Oncology, Aristotelis Bamias, MD, and colleagues found no significant advantage in overall survival with atezolizumab monotherapy vs chemotherapy in untreated patients with locally advanced or...
Immune Checkpoint Inhibitor–Induced Myocarditis: Contemporary Retrospective Analysis
In a retrospective cohort study of 160 patients with cancer who were suspected of having immune checkpoint inhibitor (ICI)-induced myocarditis, published in JACC: CardioOncology, Osnat Itzhaki Ben Zadok, MD, MSc, and colleagues found that severe ICI-induced myocarditis seemed to be linked to...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...
Novel Antibody-Drug Conjugate Under Study in Treatment of Gastric or Gastroesophageal Junction Cancers
A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may prove to be an effective treatment option for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: November 2023.1 (The ASCO Plenary Series is...
ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC
A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with...
Expert Point of View: Christopher J. Sweeney, MBBS
Invited discussant of the PSMAfore trial, Christopher J. Sweeney, MBBS, Director of the South Australian Immunogenics Cancer Institute, University of Adelaide, Australia, congratulated the authors for a well-powered, controlled phase III trial. “The study showed clear documentation of...
Improving Cancer Control in a Changing World
On October 16 and 17, 2023, the Union for International Cancer Control (UICC) welcomed more than 350 attendees from over 75 countries to its World Cancer Leaders’ Summit in Long Beach, California, to discuss some of the most challenging issues facing patients with cancer worldwide. The theme of...
LuPSMA: Another Treatment Option for Metastatic Castration-Resistant Prostate Cancer
The use of lutetium-177–labeled PSMA-617 (LuPSMA) improved radiographic progression–free survival by 57% in men with metastatic castration-resistant prostate cancer who experienced disease progression on an androgen receptor (AR) pathway inhibitor compared with changing to a new AR pathway...
NIH Immunotherapy Pioneer Steven A. Rosenberg, MD, PhD, Awarded Nation’s Highest Honor for Technology and Innovation
Immunotherapy pioneer Steven A. Rosenberg, MD, PhD, has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation’s highest honor for technological achievement. Dr. Rosenberg is Chief of the Surgery Branch at the Center for Cancer Research at the National...
I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
Overall Survival With LuPSMA vs Cabazitaxel in Previously Treated Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, overall survival results from the Australian phase II TheraP trial showed no difference with lutetium-177–labeled PSMA-617 (LuPSMA) vs cabazitaxel in patients with metastatic castration-resistant prostate cancer and...
EGFR-Mutated Advanced NSCLC: CNS Efficacy With Combination of Osimertinib and Chemotherapy
In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of...
